Hospital
Bourbon Community Hospital LLC
Bourbon Community Hospital LLC was paid $18.14M by Medicaid between Jan 2018 and Dec 2024, across 158 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.
33Billing provider infoBOURBON COMMUNITY HOSPITAL LLC
PARIS, KY 40361
PARIS, KY 40361
33aNPI1427132158assigned 10/25/2006
33bProvider typeRural Acute Care Hospital
28Total paid$18.14M
24GClaims295,470
24DCodes billed158
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Kentucky
Rank by total paid#8 of 10
Median peer was paid$23.35M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,005 | $2.91M | |
| 2019 | 39,471 | $2.54M | |
| 2020 | 42,143 | $2.45M | |
| 2021 | 44,986 | $2.41M | |
| 2022 | 44,478 | $2.57M | |
| 2023 | 45,731 | $2.53M | |
| 2024incomplete | 36,656 | $2.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 12,861 | 10,755 | $4.60M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 16,622 | 14,296 | $2.57M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.7% | 4,257 | 3,147 | $1.76M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 7.0% | 2,220 | 1,711 | $1.27M |
| G0378 | Hospital observation service, per hour | 3.6% | 1,265 | 940 | $648K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 1,029 | 850 | $613K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.3% | 9,941 | 2,600 | $604K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.7% | 1,770 | 1,404 | $487K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 4,680 | 4,242 | $468K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 2,045 | 1,536 | $462K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 6,455 | 5,447 | $417K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 6,389 | 2,600 | $279K |
146 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 3,977 | $276K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 4,984 | $231K |
| 80053 | Comprehensive metabolic panel | 1.2% | 27,766 | $226K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 4,610 | $206K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,347 | $179K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,233 | $153K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,826 | $148K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,252 | $117K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,389 | $114K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,344 | $111K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,432 | $103K |
| 73610 | <1% | 1,458 | $99K | |
| 73630 | <1% | 1,565 | $97K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,508 | $92K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,117 | $84K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,292 | $84K |
| 73562 | <1% | 960 | $73K | |
| 73130 | <1% | 1,063 | $70K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,121 | $66K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,035 | $66K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,429 | $66K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,082 | $65K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,490 | $52K |
| 80061 | Lipid panel | <1% | 4,514 | $51K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,928 | $49K |
| 97161 | <1% | 1,263 | $48K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,577 | $45K |
| 73030 | <1% | 860 | $44K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 204 | $44K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 627 | $43K |
| 84484 | <1% | 3,744 | $42K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 124 | $38K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 204 | $38K |
| 87070 | <1% | 4,951 | $37K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,291 | $34K |
| 73110 | <1% | 498 | $33K | |
| 81001 | <1% | 9,531 | $29K | |
| 81025 | <1% | 3,861 | $28K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,934 | $27K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 715 | $26K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,872 | $25K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,303 | $23K |
| 83880 | <1% | 840 | $21K | |
| 83690 | <1% | 3,063 | $17K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,755 | $17K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 567 | $17K |
| 72100 | <1% | 215 | $17K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 882 | $14K |
| 82607 | <1% | 1,397 | $14K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,351 | $14K |
| 83735 | <1% | 2,666 | $14K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,730 | $14K |
| 74018 | <1% | 134 | $14K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 925 | $14K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,432 | $13K |
| 82962 | <1% | 2,155 | $13K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 557 | $13K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,449 | $12K |
| 80354 | <1% | 1,346 | $12K | |
| 82746 | <1% | 1,056 | $11K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 369 | $11K |
| 73502 | <1% | 162 | $10K | |
| 84439 | <1% | 1,441 | $10K | |
| 71250 | <1% | 26 | $8K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 765 | $8K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 556 | $7K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 635 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 215 | $6K |
| 85610 | <1% | 2,112 | $6K | |
| 83605 | <1% | 680 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 215 | $6K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 13 | $6K |
| 87807 | <1% | 549 | $6K | |
| 85027 | <1% | 1,116 | $6K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 15 | $5K |
| 87077 | <1% | 1,002 | $5K | |
| 85379 | <1% | 644 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $5K |
| 80373 | <1% | 555 | $5K | |
| 99407 | <1% | 315 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 200 | $4K |
| 87186 | <1% | 653 | $4K | |
| 96376 | <1% | 264 | $4K | |
| 82150 | <1% | 741 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 19 | $4K |
| 82728 | <1% | 356 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 604 | $3K |
| 86480 | <1% | 67 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 387 | $3K |
| 76536 | <1% | 15 | $3K | |
| 85730 | <1% | 730 | $3K | |
| 93017 | <1% | 13 | $2K | |
| 87040 | <1% | 218 | $2K | |
| 83550 | <1% | 382 | $2K | |
| 83540 | <1% | 469 | $2K | |
| 71271 | <1% | 81 | $2K | |
| 81003 | <1% | 1,225 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,927 | $2K |
| 80074 | <1% | 64 | $2K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 405 | $2K |
| 86703 | <1% | 169 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 18 | $2K |
| 74022 | <1% | 16 | $2K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 264 | $2K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 51 | $2K |
| 97165 | <1% | 29 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 108 | $1K |
| 97164 | <1% | 26 | $1K | |
| 86706 | <1% | 130 | $1K | |
| 73090 | <1% | 14 | $1K | |
| 93971 | <1% | 16 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 254 | $977.98 |
| 86704 | <1% | 102 | $959.05 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 192 | $947.19 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 197 | $942.30 |
| 84145 | <1% | 38 | $936.99 | |
| 87340 | <1% | 99 | $920.75 | |
| 90632 | <1% | 25 | $871.44 | |
| 86140 | <1% | 237 | $750.05 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 56 | $706.36 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 84 | $682.85 |
| 84436 | <1% | 123 | $665.27 | |
| 90715 | <1% | 26 | $601.81 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 25 | $554.49 |
| 86803 | <1% | 47 | $427.06 | |
| 86708 | <1% | 43 | $424.75 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 13 | $344.90 |
| 84479 | <1% | 72 | $339.83 | |
| 94760 | <1% | 25 | $314.92 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 30 | $288.15 |
| 90656 | <1% | 19 | $245.47 | |
| G0008 | Administration of influenza virus vaccine | <1% | 18 | $239.57 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 41 | $204.40 |
| 86592 | <1% | 63 | $199.75 | |
| 86804 | <1% | 13 | $188.82 | |
| 84703 | <1% | 25 | $162.97 | |
| 0011A | <1% | 14 | $139.36 | |
| 0012A | <1% | 14 | $138.77 | |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 31 | $108.18 |
| 80076 | <1% | 14 | $98.31 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 17 | $77.88 |
| 85651 | <1% | 31 | $74.40 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 42 | $46.80 |
| 82248 | <1% | 15 | $45.42 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 18 | $44.43 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 12 | $17.49 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.